SynAct Pharma AB (SYNACT.ST)
SEK 19.02
(-2.96%)
SEK 19.02
(-2.96%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 228.01 Million SEK | 59.91% |
| 2022 | 142.59 Million SEK | 271.64% |
| 2021 | 38.36 Million SEK | 77.69% |
| 2020 | 21.59 Million SEK | -9.33% |
| 2019 | 23.81 Million SEK | 69.75% |
| 2018 | 14.02 Million SEK | -7.86% |
| 2017 | 15.22 Million SEK | -50.2% |
| 2016 | 30.57 Million SEK | 8008.83% |
| 2015 | 377 Thousand SEK | -47.86% |
| 2014 | 723 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 241.05 Million SEK | 12.98% |
| 2024 Q3 | 217.13 Million SEK | -9.92% |
| 2024 Q1 | 213.35 Million SEK | -6.43% |
| 2023 FY | 228.01 Million SEK | 59.91% |
| 2023 Q4 | 228.01 Million SEK | -17.36% |
| 2023 Q2 | 298.47 Million SEK | -7.02% |
| 2023 Q1 | 320.99 Million SEK | 125.11% |
| 2023 Q3 | 275.92 Million SEK | -7.55% |
| 2022 Q3 | 96.2 Million SEK | -28.19% |
| 2022 Q4 | 142.59 Million SEK | 48.22% |
| 2022 FY | 142.59 Million SEK | 271.64% |
| 2022 Q1 | 22.15 Million SEK | -42.26% |
| 2022 Q2 | 133.97 Million SEK | 504.73% |
| 2021 Q3 | 59.83 Million SEK | -20.51% |
| 2021 Q2 | 75.27 Million SEK | -15.37% |
| 2021 Q1 | 88.94 Million SEK | 311.92% |
| 2021 FY | 38.36 Million SEK | 77.69% |
| 2021 Q4 | 38.36 Million SEK | -35.88% |
| 2020 Q1 | 16.03 Million SEK | -32.67% |
| 2020 FY | 21.59 Million SEK | -9.33% |
| 2020 Q4 | 21.59 Million SEK | -37.26% |
| 2020 Q3 | 34.41 Million SEK | 244.19% |
| 2020 Q2 | 9.99 Million SEK | -37.64% |
| 2019 Q4 | 23.81 Million SEK | 104.96% |
| 2019 Q3 | 11.61 Million SEK | -19.96% |
| 2019 Q1 | 11.18 Million SEK | -20.25% |
| 2019 FY | 23.81 Million SEK | 69.75% |
| 2019 Q2 | 14.51 Million SEK | 29.74% |
| 2018 Q2 | 27.74 Million SEK | 93.08% |
| 2018 FY | 14.02 Million SEK | -7.86% |
| 2018 Q4 | 14.02 Million SEK | -34.12% |
| 2018 Q1 | 14.37 Million SEK | -5.61% |
| 2018 Q3 | 21.29 Million SEK | -23.26% |
| 2017 Q4 | 15.22 Million SEK | -24.64% |
| 2017 Q3 | 20.2 Million SEK | -15.33% |
| 2017 FY | 15.22 Million SEK | -50.2% |
| 2017 Q1 | 26.51 Million SEK | -13.28% |
| 2017 Q2 | 23.86 Million SEK | -9.99% |
| 2016 Q2 | 40.09 Million SEK | 0.0% |
| 2016 Q3 | 36.22 Million SEK | -9.65% |
| 2016 Q4 | 30.57 Million SEK | -15.61% |
| 2016 FY | 30.57 Million SEK | 8008.83% |
| 2015 FY | 377 Thousand SEK | -47.86% |
| 2014 FY | 723 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | -85.097% |
| Amniotics AB (publ) | 26.08 Million SEK | -774.105% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -3652.164% |
| BioArctic AB (publ) | 1.18 Billion SEK | 80.775% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 88.002% |
| Genovis AB (publ.) | 288.85 Million SEK | 21.062% |
| LIDDS AB (publ) | 17.65 Million SEK | -1191.526% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 18.198% |
| OncoZenge AB (publ) | 20.34 Million SEK | -1021.037% |
| Saniona AB (publ) | 64.14 Million SEK | -255.485% |
| Simris Alg AB (publ) | 174.55 Million SEK | -30.631% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 54.051% |
| AcouSort AB (publ) | 34.51 Million SEK | -560.676% |
| Active Biotech AB (publ) | 44 Million SEK | -418.225% |
| Camurus AB (publ) | 1.9 Billion SEK | 88.048% |
| Cantargia AB (publ) | 223.71 Million SEK | -1.925% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1433.519% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -167.543% |
| Mendus AB (publ) | 755.95 Million SEK | 69.837% |
| Kancera AB (publ) | 65.64 Million SEK | -247.362% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 81.88% |
| Lipum AB (publ) | 12.11 Million SEK | -1782.898% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -578.588% |
| NextCell Pharma AB | 81.28 Million SEK | -180.508% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 65.108% |
| Xintela AB (publ) | 18.39 Million SEK | -1139.571% |
| Ziccum AB (publ) | 14.97 Million SEK | -1422.97% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -655.705% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1037.763% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -62.179% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 70.204% |
| CombiGene AB (publ) | 120.61 Million SEK | -89.052% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -5.059% |
| Intervacc AB (publ) | 259.61 Million SEK | 12.169% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -92.502% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -265.55% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -443.433% |
| Corline Biomedical AB | 100.1 Million SEK | -127.78% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -28.736% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -266.873% |
| Aptahem AB (publ) | 63.02 Million SEK | -261.792% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 35.099% |
| Fluicell AB (publ) | 9.34 Million SEK | -2341.317% |
| Biovica International AB (publ) | 131.4 Million SEK | -73.52% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -330.346% |
| Abliva AB (publ) | 87.49 Million SEK | -160.596% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 70.005% |
| 2cureX AB (publ) | 16.62 Million SEK | -1271.543% |
| I-Tech AB | 152.44 Million SEK | -49.577% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 77.602% |
| Cyxone AB (publ) | 43.65 Million SEK | -422.32% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -189.761% |
| Biosergen AB | 7.2 Million SEK | -3066.491% |
| Nanologica AB (publ) | 77.42 Million SEK | -194.488% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -751.993% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 83.715% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -950.64% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 4.346% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -2596.854% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -161.874% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -699.842% |